51 JFK Parkway, Short Hills, NJ 07078
Category

DEA Investigations

DEA inspections, controlled substance compliance, and Drug Supply Chain Security Act enforcement.

Page 2 of 5 · 45 articles
DEA Civil Penalty Settlements for Recordkeeping Violations
DEA Investigations

DEA Civil Penalty Settlements for Recordkeeping Violations

The current per-violation cap for DEA recordkeeping findings, how DEA counts violations, and when a finding stays civil instead of…

Anthony MahajanAug 11, 2026
Closing a Pharmacy: Transferring Controlled Substance Inventory
DEA Investigations

Closing a Pharmacy: Transferring Controlled Substance Inventory

How a closing pharmacy must notify DEA before transferring inventory, take a closing count, surrender its registration, and retain…

Anthony MahajanAug 10, 2026
DEA Administrative Hearings: Process and Preparation
DEA Investigations

DEA Administrative Hearings: Process and Preparation

How the DEA administrative hearing process works under 21 CFR Part 1316, from the order to show cause through the public interest…

Anthony MahajanAug 10, 2026
ARCOS Reporting and What DEA Sees About You
DEA Investigations

ARCOS Reporting and What DEA Sees About You

ARCOS captures every controlled substance transaction from manufacturer to pharmacy, giving DEA data on your pharmacy before it op…

Anthony MahajanAug 9, 2026
Buprenorphine Prescribing After the X-Waiver Repeal
DEA Investigations

Buprenorphine Prescribing After the X-Waiver Repeal

The DATA-Waiver requirement for buprenorphine prescribing is gone, but a pharmacist's corresponding responsibility and recordkeepi…

Anthony MahajanAug 9, 2026
Perpetual Inventory as a Defense Against Shortage Findings
DEA Investigations

Perpetual Inventory as a Defense Against Shortage Findings

How a continuously reconciled perpetual inventory helps a pharmacist-in-charge document variance before a DEA shortage finding bec…

Anthony MahajanAug 8, 2026
Refusal to Fill: Balancing Diversion Risk and Patient Care
DEA Investigations

Refusal to Fill: Balancing Diversion Risk and Patient Care

How a pharmacist-in-charge weighs the corresponding responsibility to prevent diversion under 21 CFR 1306.04 against ADA patient a…

Anthony MahajanAug 8, 2026
Employee Drug Diversion: Detection and Response
DEA Investigations

Employee Drug Diversion: Detection and Response

Detection controls, internal investigation steps, and the DEA and state board reporting duties that apply once a pharmacy suspects…

Anthony MahajanAug 7, 2026
Electronic Prescribing of Controlled Substances Compliance
DEA Investigations

Electronic Prescribing of Controlled Substances Compliance

What DEA's EPCS rule under 21 CFR Part 1311 requires of a pharmacist-in-charge: identity proofing, two-factor authentication, and…

Anthony MahajanAug 7, 2026